Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Kidney Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
5 drugs · 8 active trials
17 drugs · 284 active trials
Data updated 21 minutes agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Foretinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jun 30, 2006 |
| Histamine | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 1999-06 |
| Imatinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2004-06 |
| Immunomodulatory Oligonucleotide | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2004-06 |
| Interferon Alpha-2a | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2008-02 |
| Linifanib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2007-06 |
| Mitomycin | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Sep 19, 2018 |
| Rucaparib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jun 1, 2018 |
| Seribantumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Sep 29, 2020 |
| Tandutinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2006-11 |
| Tretinoin | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2004-08 |
| Vandetanib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Aug 26, 2015 |
| Vinorelbine | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 1998-07 |
| Vistusertib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2013-02 |
| Exemestane | Phase 1 | Phase 1 | 1 | 1 | 0 | 2 | 0 | — | — | May 14, 2014 |
| Adagrasib | Phase 1 | Phase 1 | 1 | 1 | 0 | 1 | 0 | — | — | Oct 18, 2023 |
| Imiquimod | Phase 1 | Phase 1 | 1 | 0 | 0 | 1 | 0 | — | — | Apr 26, 2019 |
| Mercaptopurine | Phase 1 | Phase 1 | 1 | 0 | 0 | 1 | 0 | — | — | Dec 1, 2026 |
| Lapatinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | Sep 28, 2004 |
| Vatalanib | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | 2004-12 |
| Alpelisib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | May 14, 2014 |
| Alvespimycin | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2004-07 |
| Dacarbazine | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Dec 14, 2007 |
| Daratumumab | Phase 1 | Early Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | May 29, 2018 |
| FOLFIRI Regimen | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | May 22, 2019 |
| FOLFOX Regimen | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Nov 15, 2013 |
| HDAC Inhibitor REC-2282 | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Jul 8, 2016 |
| Interferon Alfacon-1 | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2013-07 |
| O6-Benzylguanine | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2000-06 |
| Rituximab | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Jun 21, 2011 |
| Selinexor | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Jun 26, 2015 |
| Selumetinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Dec 14, 2007 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.